Business Description
Biote Corp
NAICS : 621999
SIC : 8099
ISIN : US0906831039
Total Employee Number:
223Description
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | -0.65 | |||||
Debt-to-Equity | -1.96 | |||||
Debt-to-EBITDA | 5.48 | |||||
Interest Coverage | 1.58 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.07 | |||||
Beneish M-Score | -3.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -36.5 | |||||
3-Year EBITDA Growth Rate | 13 | |||||
3-Year Book Growth Rate | 25.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.81 | |||||
9-Day RSI | 47.24 | |||||
14-Day RSI | 43.29 | |||||
3-1 Month Momentum % | 21.74 | |||||
6-1 Month Momentum % | 20 | |||||
12-1 Month Momentum % | -16.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 108.68 | |||||
Days Sales Outstanding | 15.56 | |||||
Days Payable | 37.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.1 | |||||
Shareholder Yield % | 18.33 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.58 | |||||
Operating Margin % | 8.04 | |||||
Net Margin % | 3.19 | |||||
EBITDA Margin % | 12.79 | |||||
FCF Margin % | 9.55 | |||||
OCF Margin % | 13.28 | |||||
ROE % | Neg. Equity | |||||
ROA % | 5.69 | |||||
ROIC % | 11.85 | |||||
3-Year ROIIC % | 126.27 | |||||
ROC (Joel Greenblatt) % | 114.48 | |||||
ROCE % | 32.24 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.68 | |||||
Forward PE Ratio | 7.56 | |||||
PE Ratio without NRI | 807.5 | |||||
Price-to-Owner-Earnings | 3.58 | |||||
PS Ratio | 0.3 | |||||
Price-to-Free-Cash-Flow | 3.57 | |||||
Price-to-Operating-Cash-Flow | 2.45 | |||||
EV-to-EBIT | 8.74 | |||||
EV-to-Forward-EBIT | 1.15 | |||||
EV-to-EBITDA | 7.3 | |||||
EV-to-Forward-EBITDA | 6.55 | |||||
EV-to-Revenue | 0.93 | |||||
EV-to-Forward-Revenue | 0.93 | |||||
EV-to-FCF | 9.78 | |||||
Price-to-GF-Value | 0.5 | |||||
Earnings Yield (Greenblatt) % | 11.44 | |||||
FCF Yield % | 37.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BTMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biote Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 183.531 | ||
| EPS (TTM) ($) | 0.11 | ||
| Beta | 3.108 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.42 | ||
| Volatility % | 85.79 | ||
| 14-Day RSI | 43.29 | ||
| 14-Day ATR ($) | 0.171995 | ||
| 20-Day SMA ($) | 1.77975 | ||
| 12-1 Month Momentum % | -16.56 | ||
| 52-Week Range ($) | 1.27 - 3.62 | ||
| Shares Outstanding (Mil) | 28.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biote Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biote Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 17:00 | In 74 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 73 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | 2.27 (-0.44%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 2.27 (-0.44%) | ||
| General meeting for 2026 | 2026-05-12 10:00 | 2.21 (+1.38%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 17:00 | 2.21 (+4.25%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 2.21 (+4.25%) | ||
| Annual report for 2025 | 2026-03-13 | 1.54 (-7.23%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-11 17:00 | 1.70 (-5.03%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 1.70 (-5.03%) |
Show
Entries
Biote Corp Frequently Asked Questions
What is Biote Corp(BTMD)'s stock price today?
The current price of BTMD is $1.62. The 52 week high of BTMD is $3.62 and 52 week low is $1.27.
When is next earnings date of Biote Corp(BTMD)?
The next earnings date of Biote Corp(BTMD) is 2026-11-05 Est..
Does Biote Corp(BTMD) pay dividends? If so, how much?
Biote Corp(BTMD) does not pay dividend.
Press Release
Articles on Biote Corp
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and Strategic Shifts
Aug 06, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers